TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Pharmaceutical Preparations · NYSE · SEC CIK 818686 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-16.4%
TTM net income YoY-28.9%
TTM EPS YoY-29.5%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR—
Margins
Gross margin65.8%
Operating margin10.2%
Net margin3.6%
FCF margin8.8%
EBITDA margin17.3%
Returns
ROE6.6%
ROA1.3%
ROIC (approx.)32.1%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets80.1%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.50x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $17.26B | $16.54B |
| Cost of revenue | $8.32B | $8.48B |
| Gross profit | $8.94B | $8.06B |
| R&D expense | $1.01B | $998.00M |
| SG&A expense | $1.29B | $1.16B |
| Operating income | $2.16B | -$303.00M |
| Interest expense | $916.00M | $1.00B |
| Pretax income | $1.22B | -$1.28B |
| Income tax | -$180.00M | $676.00M |
| Net income | $1.41B | -$1.64B |
| EBITDA | $3.16B | $756.00M |
| EPS (basic) | 1.23 | -1.45 |
| EPS (diluted) | 1.21 | -1.45 |
| Weighted avg. shares (diluted) | 1.16B | 1.13B |
| Balance sheet | ||
| Cash & equivalents | $3.56B | $3.30B |
| Receivables | $3.71B | $3.06B |
| Inventory | $3.18B | $3.01B |
| Current assets | $13.95B | $12.55B |
| PP&E, net | $4.08B | $4.58B |
| Goodwill | $16.00B | $16.00B |
| Intangibles | $3.78B | $4.42B |
| Total assets | $40.75B | $39.33B |
| Current liabilities | $13.46B | $12.80B |
| Short-term debt | $1.82B | $1.78B |
| Total liabilities | $32.83B | $33.61B |
| Shareholders' equity | $7.91B | $5.37B |
| Cash flow statement | ||
| Operating cash flow | $1.65B | $1.25B |
| Capital expenditure | $501.00M | $498.00M |
| Free cash flow | $1.15B | $749.00M |
| Investing cash flow | $737.00M | $792.00M |
| Financing cash flow | -$2.15B | -$1.79B |
| Depreciation & amortization | $1.00B | $1.06B |
| Stock-based compensation | $157.00M | $123.00M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.